Table 9

Adjuvant chemotherapy and adjuvant trastuzumab by tumour and patient characteristics in HER2-positive pT1a and pT1b breast cancers (n = 49)
All HER2-positive tumours HER2-positive tumours treated with adjuvant chemotherapy* HER2-positive tumours treated with adjuvant chemotherapy and trastuzumab *
No. of patients 49 36 (73.5%) 30 (61.2%)
Menopausal status
pre- 19 18 (94.7%) 14 (73.7%)
post- 30 18 (60.0%) 16 (53.3%)
Age (years)
18–34 2 2 (100.0%) 2 (100.0%)
35–49 17 17 (100.0%) 12 (70.6%)
50–69 25 16 (64.0%) 15 (60.0%)
≥ 70 5 1 (20.0%) 1 (20.0%)
Hormonal receptor status
positive 29 18 (62.1%) 15 (51.7%)
negative 20 18 (90.0%) 15 (75.0%)
LN status
pN0 43 30 (69.7%) 24 (55.8%)
pN1 4 4 (100.0%) 4 (100.0%)
pN2 2 2 (100.0%) 2 (100.0%)
Grading
G1 2 1 (50.0%) 0 (0.0%)
G2 23 16 (69.6%) 13 (56.5%)
G3 19 16 (84.2%) 16 (84.2%)

* Values and percentages are based on the all HER2-positive patients

Gori et al.

Gori et al. BMC Cancer 2012 12:158   doi:10.1186/1471-2407-12-158

Open Data